1,630 Shares in Bristol-Myers Squibb (NYSE:BMY) Purchased by Tidemark LLC

Tidemark LLC purchased a new position in shares of Bristol-Myers Squibb (NYSE:BMY) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 1,630 shares of the biopharmaceutical company’s stock, valued at approximately $84,000.

A number of other hedge funds have also bought and sold shares of BMY. Delta Asset Management LLC TN grew its holdings in shares of Bristol-Myers Squibb by 7.6% during the 4th quarter. Delta Asset Management LLC TN now owns 77,464 shares of the biopharmaceutical company’s stock valued at $3,975,000 after purchasing an additional 5,488 shares during the last quarter. Alpha Family Trust acquired a new stake in Bristol-Myers Squibb during the 4th quarter worth approximately $365,000. Financial Advisors Network Inc. boosted its position in Bristol-Myers Squibb by 5.9% during the 4th quarter. Financial Advisors Network Inc. now owns 4,554 shares of the biopharmaceutical company’s stock worth $234,000 after buying an additional 254 shares during the period. Pzena Investment Management LLC boosted its position in Bristol-Myers Squibb by 13.6% during the 4th quarter. Pzena Investment Management LLC now owns 5,592,816 shares of the biopharmaceutical company’s stock worth $286,967,000 after buying an additional 668,622 shares during the period. Finally, Central Valley Advisors LLC acquired a new stake in Bristol-Myers Squibb during the 4th quarter worth approximately $200,000. 76.41% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently issued reports on BMY shares. BMO Capital Markets dropped their price target on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday, April 26th. Societe Generale downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Wells Fargo & Company boosted their price target on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 18th. Redburn Atlantic downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their target price for the company from $77.00 to $54.00 in a research report on Tuesday, February 6th. Finally, Barclays dropped their target price on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research report on Friday, April 26th. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus target price of $60.00.

Bristol-Myers Squibb Price Performance

BMY traded down $0.45 on Thursday, reaching $41.89. The company had a trading volume of 4,845,826 shares, compared to its average volume of 15,427,265. The company has a market cap of $84.92 billion, a price-to-earnings ratio of -13.51, a P/E/G ratio of 14.31 and a beta of 0.45. Bristol-Myers Squibb has a 52-week low of $41.58 and a 52-week high of $66.69. The business has a 50 day simple moving average of $48.24 and a 200 day simple moving average of $49.80. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, topping the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. During the same period in the previous year, the firm earned $2.05 earnings per share. The firm’s revenue for the quarter was up 4.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Bristol-Myers Squibb will post 0.59 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, May 1st. Investors of record on Friday, April 5th were issued a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 5.73%. The ex-dividend date of this dividend was Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -77.42%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.